XNAS
PSNL
Market cap1.71bUSD
Oct 08, Last price
16.06USD
1D
0.38%
1Q
14.14%
IPO
-46.91%
Name
Personalis Inc
Chart & performance
P/E
—
P/S
24.62
EPS
—
Div yield, %
—
Shrs. gr., 5y
21.02%
Rev. gr., 5y
-2.40%
Revenues
70m
-17.69%
Net income
-81m
L-0.02%
CFO
-75m
L+65.99%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microenvironments, even from small tissue or plasma samples. This platform encompasses several specialized solutions: ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for plasma analysis; NeXT Personal, a specific liquid biopsy designed for individual patient tumor tracking; the NeXT Dx Test, a genomic cancer profiling tool that identifies composite biomarkers for treatment guidance; and the sophisticated NeXT SHERPA and NeXT NEOPS for predicting neoantigens. Additionally, Personalis offers the ACE platform, utilized for diverse clinical and therapeutic applications like neoantigen prediction, biomarker identification, and the selection of new drug targets. Their clientele includes biopharmaceutical companies, academic institutions, non-profit organizations, and government entities. The company has established significant partnerships with organizations such as Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center. Personalis, Inc. was founded in 2011 and is based in Menlo Park, California.
Key people
Richard Chen
Chief Science Officer · since 2011
Michael J. Fitzpatrick
Vice President - Worldwide Sales · since 2013
Christian D. Haudenschild
Vice President - Genomic Services
Clinton Musil
Chief Business Officer · since 2018
Independent Director · since 2019
Carol J. Tillis
Vice President - Finance and Administration
Legal address
C/O Incorporating Services, Ltd.
3500 South DuPont Highway
Dover, DE 19901
US
3500 South DuPont Highway
Dover, DE 19901
US
Headquarters
1350 Willow Road
Suite 202
Menlo Park, CA 94025
US
Suite 202
Menlo Park, CA 94025
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||